Sinopharm Group Co Class H ( (SHTDF) ) has released its Q2 earnings. Here is a breakdown of the information Sinopharm Group Co Class H presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sinopharm Group Co. Ltd., a leading pharmaceutical distribution company in China, is primarily engaged in the distribution of pharmaceutical products, medical devices, and the operation of chain pharmacy stores. The company operates in the healthcare sector and is known for its extensive distribution network and comprehensive service offerings.
In its 2025 interim earnings report, Sinopharm Group announced a decrease in revenue and profit compared to the previous year. The company reported a revenue of RMB 286 billion, a 2.95% decline from the same period last year, and a net profit of RMB 5.34 billion, marking a 9.53% decrease.
Key financial metrics highlighted in the report include a gross profit of RMB 20.35 billion and an operating profit of RMB 7.45 billion. The pharmaceutical distribution segment, which constitutes the majority of the company’s revenue, saw a slight decrease in revenue, while the retail pharmacy segment experienced growth. The company also reported improvements in expense control, with reductions in selling, administrative, and financial expenses.
Looking ahead, Sinopharm Group aims to strengthen its compliance management and risk control measures while focusing on sustainable business development. The company plans to continue optimizing its operational efficiency and enhancing its service capabilities to adapt to the evolving market conditions and regulatory environment.